Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 190,022 |
|
|||||
| News | - | ||||||
| Day High | 2.20 | Low High |
|||||
| Day Low | 1.99 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Eledon Pharmaceuticals Inc | ELDN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.14 | 6.93% | 2.16 | 17:12:57 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.01 | 1.99 | 2.20 | 2.16 | 2.02 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 627 | 190,022 | $ 2.11 | $ 401,107 | - | 1.07 - 2.95 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:55:30 | formt | 100 | $ 2.16 | USD |
Eledon Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 52.27M | 24.20M | - | 0 | -40.33M | -1.67 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Eledon Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ELDN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.64 | 2.20 | 1.55 | 1.94 | 220,976 | 0.52 | 31.71% |
| 1 Month | 2.04 | 2.20 | 1.52 | 1.88 | 117,776 | 0.12 | 5.88% |
| 3 Months | 1.82 | 2.23 | 1.5199 | 1.86 | 86,387 | 0.34 | 18.68% |
| 6 Months | 1.32 | 2.23 | 1.07 | 1.67 | 88,416 | 0.84 | 63.64% |
| 1 Year | 2.61 | 2.95 | 1.07 | 1.84 | 113,224 | -0.45 | -17.24% |
| 3 Years | 10.51 | 11.69 | 1.07 | 3.23 | 71,551 | -8.35 | -79.45% |
| 5 Years | 15.80 | 22.91 | 1.07 | 4.22 | 71,072 | -13.64 | -86.33% |
Eledon Pharmaceuticals Description
| Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody. |
